Acute Respiratory Distress Syndrome (ARDS) Market Size, Share, Trends, Growth 2032

Acute Respiratory Distress Syndrome (ARDS) Industry Prospective:

The global acute respiratory distress syndrome (ARDS) market size was evaluated at $130 billion in 2023 and is slated to hit $280 billion by the end of 2032 with a CAGR of nearly 11% between 2024 and 2032.

Request Free Sample

Acute Respiratory Distress Syndrome (ARDS) Market: Overview

Acute respiratory distress syndrome is a severe lung condition that leads to lung inflammation and a reduction in blood oxygen levels. It can be caused by various factors, such as trauma, sepsis, pneumonia, acute pancreatitis, inhaling hazardous substances, and blood transfusions.

Key Insights

• As per the analysis shared by our research analyst, the global acute respiratory distress syndrome (ARDS) market is projected to expand annually at the annual growth rate of around 11% over the forecast timespan (2024-2032)
•  In terms of revenue, the global acute respiratory distress syndrome (ARDS) market size was evaluated at nearly $130 billion in 2023 and is expected to reach $280 billion by 2032.
• The global acute respiratory distress syndrome (ARDS) market is anticipated to grow rapidly over the forecast timeline owing to an increase in the cases of acute respiratory distress syndrome and breakthroughs in diagnostics & therapeutic systems.
• In terms of cause, the pneumonia segment is slated to register the highest CAGR over the forecast period.
• Based on treatment, the mechanical ventilation segment is predicted to contribute majorly towards global industry surge in the ensuing years.
• On the basis of severity, the severe ARDS segment is likely to maintain segmental domination in the forthcoming years.
• Based on the end-user, the hospitals segment is predicted to record highest gains in the forecast period.
• Region-wise, the Asia-Pacific acute respiratory distress syndrome (ARDS) industry is projected to register the fastest CAGR during the assessment timespan.

Acute Respiratory Distress Syndrome (ARDS) Market: Growth Factors

A surge in the frequency of disease occurrence can prop up the global market expansion over 2024-2032

An increase in the cases of acute respiratory distress syndrome and breakthroughs in diagnostics & therapeutic systems will steer the expansion of the global acute respiratory distress syndrome (ARDS) market. Furthermore, a surge in investments in research activities focusing on developing new modes of treatment can proliferate the size of the market globally.

Moreover, the launch of new diagnostic equipment, such as blood gas analyzers and capnography equipment for detecting disease in the early phase, will promote global market trends. In addition, the evolution of new medical treatments, such as ExoFlo and Sabizabulin, is likely to bring a paradigm shift in the global market. Supportive government policies will aid the growth of the global market.

Acute Respiratory Distress Syndrome (ARDS) Market: Restraints

Lack of access to advanced modes of treating disease can restrict the global industry surge over forecast period

An increase in the rate of mortality, along with the availability of low treatment alternatives in developing nations, can retard the growth of the global acute respiratory distress syndrome (ARDS) industry. For instance, a lack of proficient pharmacological treatments can hamper the expansion of the industry globally.  

Acute Respiratory Distress Syndrome (ARDS) Market: Opportunities

Accessibility of advanced healthcare facilities to open new growth avenues for the global market

Easy availability of improved healthcare amenities, along with the focus of the government on increasing the expenditure on improving the healthcare infrastructure, is likely to open new growth avenues for the global acute respiratory distress syndrome (ARDS) market. Moreover, introduction of new treatments and medicines targeting ARDS will impel the global market elevation.

Acute Respiratory Distress Syndrome (ARDS) Market: Challenges

Clinical experiments have failed to produce beneficial results, which can hinder the global industry surge

Significant biological differences between the patients can complicate the treatment of the disease, thereby challenging the growth of the global acute respiratory distress syndrome (ARDS) industry. Furthermore, randomized controlled trials have failed to produce beneficial outcomes and this can obstruct the growth of the global industry.

Acute Respiratory Distress Syndrome (ARDS) Market: Segmentation

The global acute respiratory distress syndrome (ARDS) market is divided into cause, severity, treatment, end-user, and region.                                             

In terms of cause, the acute respiratory distress syndrome (ARDS) market across the globe is segmented into sepsis, trauma, and pneumonia segments. Apparently, the pneumonia segment, which garnered nearly half of the global market revenue in 2023, is projected to record the fastest CAGR in the next couple of years as a result of an increase in the bacterial & viral cases of pneumonia. Additionally, the easy availability of various treatments for pneumonia strains can shape the segmental surge.   

Based on treatment, the global acute respiratory distress syndrome (ARDS) industry is sectored into medication, mechanical ventilation, extracorporeal membrane oxygenation, and oxygen therapy segments. Furthermore, the mechanical ventilation segment, which dominated the global industry size in 2023, is likely to contribute substantively toward the global industry elevation over 2024-2032. This can be due to the ability of mechanical ventilation to provide respiratory aid to subjects whose lungs cannot adequately provide oxygen in the blood.

On the basis of severity, the global acute respiratory distress syndrome (ARDS) market is segregated into mild ARDS, severe ARDS, and moderate ARDS segments. Moreover, the severe ARDS segment, which dominated the segmental surge in 2023, is projected to retain a segmental leadership position in the forecasting timeline owing to the need for intense treatment for severe ARDS, such as advanced ventilation strategies and ECMO. Reportedly, patients suffering from severe ARDS require huge stays in intensive care units in hospitals, thereby leading to high resource utilization. This, in turn, will prop up the segmental surge.

Based on the end-user, the acute respiratory distress syndrome (ARDS) industry globally is bifurcated into home care, hospitals, and clinics segments. Moreover, hospital segment, which led the segmental expansion in 2023, is predicted to register the highest gains over 2024-2032, subject to a rise in the number of patients affected due to acute respiratory distress syndrome along with the presence of advanced healthcare infrastructure facility in developed as well as emerging economies. Supportive compensation policies and advanced facilities in hospitals for treating patients are likely to drive the segmental surge.   

Acute Respiratory Distress Syndrome (ARDS) Market: Report Scope

Acute Respiratory Distress Syndrome (ARDS) Market: Regional Insights

North America is projected to maintain leading position in the global market over the projected timespan

North America, which accounted for about 70% of the global acute respiratory distress syndrome (ARDS) market size in 2023, is expected to establish a leadership post in the global market during the forecasting timeline. In addition to this, the regional market elevation in the coming eight years can be credited to the presence of strong infrastructure facilities in countries such as Canada and the U.S.

Moreover, surging cases of ARDS in North America, along with the presence of key players in the region will steer the regional market surge. High focus of the government on critical care management, along with high awareness regarding the occurrence, diagnosis, and treatment of the disease, has driven the growth of the market in the region.

The Asia-Pacific acute respiratory distress syndrome (ARDS) industry is anticipated to register the highest CAGR in the expected timeframe. The swift elevation of the industry in Asia-Pacific can be ascribed to a massive rise in the fund allocation in the healthcare sector along with the availability of advanced healthcare amenities in countries such as Japan, India, and China. Surging geriatric population prone to suffering from the ailment will enunciate the industry expansion in the APAC sub-continent.

Acute Respiratory Distress Syndrome (ARDS) Market: Competitive Space

The global acute respiratory distress syndrome (ARDS) market profiles key players such as:

• Faron Pharmaceuticals
• Athersys
• Drägerwerk AG & Co. KGaA
• LivaNova PLC
• HEALIOS K.K.
• Medtronic Corporation
• Hamilton Company
• GE Healthcare
• BioMarck Pharmaceuticals
• Apeptico Forschung
• Fisher & Paykel Healthcare Limited
• United Therapeutics

The global acute respiratory distress syndrome (ARDS) market is segmented as follows:

By Cause

• Sepsis
• Trauma
• Pneumonia

By Severity

• Mild ARDS
• Severe ARDS
• Moderate ARDS

By Treatment

• Medication
• Mechanical Ventilation
• Extracorporeal Membrane Oxygenation
• Oxygen Therapy

By End-User

• Home Care
• Hospitals
• Clinics

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France 
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa